Shares of Johnson & Johnson (JNJ) continued lower during Wednesday’s session due to a highly publicized trial against the multinational company in the state of Oklahoma. Investors have been skittish over the lead-up to the trial and its massive implications regarding the nationwide opioid crisis, scaring them into dragging the stock down to its lowest […]
Read MoreGood bargains may be hard to come by right now, but these 2 stocks look ripe for the picking.
Read MoreIronwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA […]
Read MoreThe market’s rally from a low point on Christmas Eve last year has given a lot of investors reason to think that the worst of the correction before that, which tested bear market territory for all of the major market indices, is probably done. With seemingly positive news on the trade front working along with […]
Read MoreRigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company’s clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study […]
Read MoreTenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction […]
Read MoreCuris, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse […]
Read MoreInnoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), […]
Read MoreCVS Health Corp. (CVS) reported Q4 earnings on Wednesday, and the company disappointed with a lower-than-expected earnings forecast for the rest of 2019. Investors primarily focused on the weak guidance over earnings per share (EPS), which surpassed Wall Street estimates by a solid margin. Today’s performance marks a seismic shift in the company’s history from […]
Read MoreArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company offers ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver disease related to alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial […]
Read More